Roth Capital Cuts Earnings Estimates for Aptevo Therapeutics

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Roth Capital decreased their Q1 2025 earnings per share (EPS) estimates for shares of Aptevo Therapeutics in a research report issued to clients and investors on Monday, February 17th. Roth Capital analyst J. Aschoff now anticipates that the biotechnology company will earn ($4.21) per share for the quarter, down from their prior forecast of ($3.92). The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($15.84) per share. Roth Capital also issued estimates for Aptevo Therapeutics’ Q2 2025 earnings at ($4.16) EPS, Q3 2025 earnings at ($3.78) EPS, Q4 2025 earnings at ($3.74) EPS, FY2025 earnings at ($15.84) EPS, FY2026 earnings at ($14.49) EPS, FY2027 earnings at ($10.03) EPS and FY2028 earnings at ($3.57) EPS.

Separately, StockNews.com initiated coverage on Aptevo Therapeutics in a research note on Monday, December 9th. They set a “sell” rating on the stock.

Aptevo Therapeutics Stock Up 2.5 %

NASDAQ:APVO opened at $3.50 on Thursday. Aptevo Therapeutics has a twelve month low of $3.01 and a twelve month high of $399.60. The business has a 50 day moving average price of $4.36 and a two-hundred day moving average price of $234.52.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.